Savara Inc (SVRA) Receives a Buy from Jefferies


Jefferies analyst David Steinberg reiterated a Buy rating on Savara Inc (NASDAQ: SVRA) today and set a price target of $17. The company’s shares opened today at $10.91.

According to TipRanks.com, Steinberg is a 4-star analyst with an average return of 10.5% and a 49.6% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Supernus Pharmaceuticals, and Collegium Pharmaceutical.

Currently, the analyst consensus on Savara Inc is a Strong Buy with an average price target of $26, which is a 138.3% upside from current levels. In a report issued on August 2, Canaccord Genuity also maintained a Buy rating on the stock with a $25 price target.

.

See today’s analyst top recommended stocks >>

Based on Savara Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $26.85 million. In comparison, last year the company had a GAAP net loss of $11.5 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts